<code id='4D2FEFBB8F'></code><style id='4D2FEFBB8F'></style>
    • <acronym id='4D2FEFBB8F'></acronym>
      <center id='4D2FEFBB8F'><center id='4D2FEFBB8F'><tfoot id='4D2FEFBB8F'></tfoot></center><abbr id='4D2FEFBB8F'><dir id='4D2FEFBB8F'><tfoot id='4D2FEFBB8F'></tfoot><noframes id='4D2FEFBB8F'>

    • <optgroup id='4D2FEFBB8F'><strike id='4D2FEFBB8F'><sup id='4D2FEFBB8F'></sup></strike><code id='4D2FEFBB8F'></code></optgroup>
        1. <b id='4D2FEFBB8F'><label id='4D2FEFBB8F'><select id='4D2FEFBB8F'><dt id='4D2FEFBB8F'><span id='4D2FEFBB8F'></span></dt></select></label></b><u id='4D2FEFBB8F'></u>
          <i id='4D2FEFBB8F'><strike id='4D2FEFBB8F'><tt id='4D2FEFBB8F'><pre id='4D2FEFBB8F'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:8
          Stock exchange
          Drew Angerer/Getty Images

          Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

          In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

          advertisement

          Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          In utero gene editing: an explainer
          In utero gene editing: an explainer

          AnnaYeo/STATRecentlyapprovedgenetherapiesofferpatientsone-time,potentiallycurativetreatmentsforgenet

          read more
          Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
          Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

          FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

          read more

          New documents shed light on MD Anderson Cancer Institute feud

          AdobeEarlylastyear,MDAndersonCancerCenterleadershiphadaproblemontheirhands:acontentiousdisputebetwee